Diabetic retinopathy refers to an eye disorder that damages or harms the
blood vessels of the retina. Diabetic retinopathy can cause permanent
blindness. Chronic diabetes is a major root of diabetic retinopathy.
The treatment procedure of diabetic retinopathy depends
on the various stages of diabetic retinopathy. It is one of the most dominant
reasons of blindness in U.S adults. According to WHO, about 347 million
patients were suffering from diabetes globally as of 2012, and among those 347
million patients 11% of those were effected from diabetic retinopathy. In
the U.S. alone, there were 4.1 million people were impacted from the diabetic
retinopathy as of 2012.
North America was the largest market for diabetic
retinopathy in 2014. The market dominance of North America is attributed to the
high obesity rate and large diabetic patients in this region. Moreover the
supportive government initiative is also one of the important drivers of the
market in this region.
Europe was the second largest market of diabetic
retinopathy in 2014, the large population of baby boomers in Europe is one of
the dominate growth factors for the diabetic retinopathy market in this region.
Asia Pacific is expected to show the highest growth over the next five years.
The lucrative growth of the diabetic retinopathy market in Asia Pacific is
attributed to the presence of a large number of diabetic patients in India and
China. Moreover, growing health awareness coupled with rising expenditure on
healthcare services is also fueling the diabetic retinopathy market in this
region. Country wise the U.S. is the largest market of diabetic retinopathy in
North America. Germany, Spain, Italy, U.K and France are some of the major
diabetic retinopathy market in Europe. China, Japan, India are some of the
major market diabetic retinopathy in Asia Pacific region. Under Rest of the
World section Brazil is the largest market of diabetic retinopathy.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-retinopathy-market
Some of the major players operating in the global
diabetic retinopathy market include, Bayer AG, Pfizer Inc., F. Hoffmann-La
Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Valeant
Pharmaceuticals International Inc., Abbott Laboratories Ltd., Alimera Sciences
Inc., Ampio Pharmaceuticals Inc., Bausch & Lomb Inc., Boehringer Ingelheim
GmbH, iCo Therapeutics Inc., Lupin Ltd., Parexel International Corp., Quark
Pharmaceuticals Inc., Thrombogenics NV, and Vitreoretinal Technologies
Inc.
